Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. - Wikidata - wikimedia - TriplyDB

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

http://www.wikidata.org/entity/Q42458249

about

Role of positron emission tomography for the monitoring of response to therapy in breast cancer Human breast cancer metastases to the brain display GABAergic properties in the neural niche.Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.Correlation Factors Analysis of Breast Cancer Tumor Volume Doubling Time Measured by 3D-Ultrasound Biological subtypes of breast cancer: Prognostic and therapeutic implications.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry.mCOPA: analysis of heterogeneous features in cancer expression data.Molecular Heterogeneity of Triple Negative Breast Cancer.Subtyping of triple-negative breast cancer: implications for therapy Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Invasive Breast Cancer: Recognition of Molecular Subtypes Luminal-B breast cancer and novel therapeutic targets.Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series.Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.Update on triple-negative breast cancer: prognosis and management strategies Variation of ATM Gene Expression in Peripheral Blood Cells of Sporadic Breast Carcinomas in Iranian Patients Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study Breast cancer as a systemic disease: a view of metastasis Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer Molecular profiling for breast cancer: a comprehensive review.Identifying subgroup markers in heterogeneous populations.Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors.Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.DNA amplifications in breast cancer: genotypic-phenotypic correlations.Beyond triple-negative breast cancer: the need to define new subtypes.Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.Molecular tests as prognostic factors in breast cancer.Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound.

P2860

Q28080621-5B9434FA-25EB-47A6-B7AB-341EFD0115D4 Q30569512-74A27A3B-8E04-4315-8E9C-C140D828C217 Q31034941-7FAE9844-14DD-4C13-A85D-0D17CC19FC80 Q33874429-5B1E273D-1C82-488C-B0DE-E88296406A05 Q34023695-624F2955-A5B7-4E7D-8822-2A02FC2BB710 Q34109691-E10C0958-C870-48C9-9686-C3106052E994 Q34423470-D13DC7CE-182D-4FB1-B5AE-BC47229C9039 Q34502379-0EFFFBDE-A3EB-4BA2-8E6C-9B8B125B0ED0 Q34533964-1908472C-9002-4BB1-AC0A-1CFBF95245CE Q34734477-8A5BD684-77F3-498C-A0BF-E269E97BF98D Q35119701-39189023-6DAE-45E0-89CA-AE52C58CAEED Q35144029-AF0A9A88-0E89-4E10-97F3-C5F6AB951396 Q35558070-3AA3DD5D-9459-4B38-852A-FDF3A4FFA9DC Q35576242-836C0721-7E90-4B79-AEA1-CD367143185D Q35889534-A6A25811-1521-4912-9E29-67193E50C98D Q35941288-81EDD4A5-EB74-4956-A482-E4835D8E1E21 Q36024666-A63BF803-9C7D-4C74-BF94-1ABCA5C4CE1D Q36086056-73F5EA40-4A43-45C9-910B-31E3A6238654 Q36187733-2CE309AF-DA9E-4391-821A-A14138F6768B Q36295737-366C2055-39D1-4A52-86D9-D9647B2CEE01 Q36311616-A6395268-9876-46D5-A93D-A40769139579 Q36571440-CDF3EB94-E91E-4DB4-A3F4-443CCE7A3D7A Q36868191-01F1C9E6-9199-4081-A5F1-B512209ADC03 Q37011741-6C2404C9-A7AB-43EA-9F07-0C9D4481F819 Q37156474-30BBD8DF-C9C2-4483-925D-66966B0BB43D Q37302484-E9763AD1-A2E5-4B08-868F-6C75FEA9AEA6 Q37327650-55BF5D4A-0DEA-4E84-BC73-81B98AEBB7E5 Q37425194-46479DE0-30D4-4F6E-95D8-95872011AE83 Q37582430-E16642B7-0E4A-4A1F-A074-63E379AF4570 Q37763102-D86F6D3C-4124-4169-BBF1-B84008A21351 Q37782088-A6A847F4-D67C-47DC-8A14-BB39EE56A0C5 Q37809456-95B81279-1A46-491B-B4EA-98BB8A9729F3 Q37848654-D30F3FB8-8E7C-4A06-BEB7-E56A57FF67BE Q37903140-C27E531D-736D-4DA1-84B7-75415605FA8B Q38059133-026AE430-FD30-460E-9E87-FC6AA5204F2D Q38061108-32712D5D-F310-45BC-9AAE-78A2855ECA84 Q38184381-79160FD4-CBAF-42D5-B9FE-0F95C9C20DD5 Q38250247-2C1D7DCC-CEB6-4349-8A5C-11734DD0769E Q38422177-18E6D09B-8C09-4969-8B07-A3D470508067 Q38437589-73FDEC4C-E1E6-4092-A42B-4911676F2EFE

P2860

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

http://www.wikidata.org/entity/Q42458249

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Concordance of clinical and mo ...... erative chemotherapy response.

@en

Concordance of clinical and mo ...... erative chemotherapy response.

@nl

type

label

Concordance of clinical and mo ...... erative chemotherapy response.

@en

Concordance of clinical and mo ...... erative chemotherapy response.

@nl

prefLabel

Concordance of clinical and mo ...... erative chemotherapy response.

@en

Concordance of clinical and mo ...... erative chemotherapy response.

@nl

P1433

Q42458249-A4455178-D081-4004-B4A3-D00857433AA1

P1476

Q42458249-715EBB94-B410-4DD1-830B-7D2B42CF66CE

P2093

Q42458249-3608B3FA-CBD3-4B46-A5AE-8A8792CD466B

Q42458249-67BBCFDB-18BD-43CD-A652-C8E9F6BBBDD7

Q42458249-73F28F42-8453-496B-A02E-4D112409E533

Q42458249-8F46C191-2B02-44F8-B079-0A545018CBF6

Q42458249-971F6E34-2CB9-4494-9166-7FE4DAE96D2F

Q42458249-C11F3C8A-A209-44BE-B7E0-BC25076F3882

Q42458249-D6306708-53FB-4447-844E-D962651F9414

Q42458249-F57DF443-EAF9-45DB-801A-887152087986

Q42458249-F82B5F8F-2F64-493C-BE8F-042C8EECC2CB

P2888

Q42458249-BBB45115-7A1D-4B0D-B4F1-1852382D09F3

P304

Q42458249-802DD964-01AE-45AE-8401-0C995BE1A02A

P31

Q42458249-505F12B5-ACBA-4FFF-939E-9F8EECF417FD

P356

Q42458249-4B4D134B-5C1F-461D-BDEF-867DC51D3401

P407

Q42458249-1D373685-4BAC-42CD-9F17-E0B0E5EE09EB

P433

Q42458249-D23BED8E-C278-497D-8B1A-F44597865A6D

P478

Q42458249-06DC1729-37C9-4270-B366-4F9C662416CA

P50

Q42458249-5E3642C2-C900-48BF-98C1-65A5AB4D8282

P577

Q42458249-742C1ED1-AAC6-47A2-B4B9-5D0B3ABC6FEE

P5875

Q42458249-17BDF709-0357-4231-9A6F-B9E84AD80504

P6179

Q42458249-D816DCA3-1330-4868-90A6-548658C8BD5F

P698

Q42458249-087C2FB7-277D-464B-AA6A-B85BCE9381F0

P921

Q42458249-782D1F1F-66A2-4947-A60C-0BC356ADED0C

P356

S10549-009-0499-6

P1433

Breast Cancer Research and Treatment

P1476

Concordance of clinical and mo ...... erative chemotherapy response.

@en

P2093

Hans Halfwerk

http://www.w3.org/2001/XMLSchema#string

Jelle Wesseling

http://www.w3.org/2001/XMLSchema#string

Jorma J de Ronde

http://www.w3.org/2001/XMLSchema#string

Juliane Hannemann

http://www.w3.org/2001/XMLSchema#string

Lennart Mulder

http://www.w3.org/2001/XMLSchema#string

Lodewyk F A Wessels

http://www.w3.org/2001/XMLSchema#string

Marie-Jeanne T F D Vrancken Peeters

http://www.w3.org/2001/XMLSchema#string

Marieke E Straver

http://www.w3.org/2001/XMLSchema#string

Sjoerd Rodenhuis

http://www.w3.org/2001/XMLSchema#string

P2888

s10549-009-0499-6

P304

119-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-009-0499-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Marc van de Vijver

P577

2009-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26730975

http://www.w3.org/2001/XMLSchema#string

P6179

1009490783

http://www.w3.org/2001/XMLSchema#string

P698

19669409

http://www.w3.org/2001/XMLSchema#string

P921